Advanced search
Publication Cover
Expert Opinion on Orphan Drugs Volume 4, 2016 - Issue 2
Submit an article Journal homepage
90
Views
14
CrossRef citations to date
0
Altmetric
Review

Histaminergic modulation in Tourette syndrome

Joanna H. CoxHeart of England NHS Foundation Trust, Birmingham, UK
,
Stefano SeriSchool of Life and Health Sciences, Aston Brain Centre, Aston University, Birmingham, UK;Children’s Epilepsy Surgery Programme, The Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, UK
&
Andrea E. CavannaSchool of Life and Health Sciences, Aston Brain Centre, Aston University, Birmingham, UK;Department of Neuropsychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK;Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology and UCL, London, UKCorrespondence[email protected]
Pages 205-213 | Received 27 Sep 2015, Accepted 03 Dec 2015, Published online: 05 Jan 2016

References

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Rickards H, Cavanna AE. Gilles de la Tourette: the man behind the syndrome. J Psychosom Res. 2009;67:469–474.
  • Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord. 2011;26:1149–1156.
  • McNaught KS, Mink JW. Advances in understanding and treatment of Tourette syndrome. Nat Rev Neurol. 2011;7:667–676.
  • Cavanna AE, Seri S. Tourette’s syndrome. Br Med J. 2013;347:f4964.
  • Ganos C, Martino D. Tics and Tourette syndrome. Neurol Clin. 2015;33:115–136.
  • Martino D, Madhusudan N, Zis P, et al. An introduction to the clinical phenomenology of Tourette syndrome. Int Rev Neurobiol. 2013;112:1–32.
  • Woods DW, Piacentini J, Himle MB, et al. Premonitory Urge for Tics Scale (PUTS): initial psychometric results and examination of the premonitory urge phenomenon in youths with Tic disorders. J Dev Behav Pediatr. 2005;26:397–403.
  • Steinberg T, Shmuel Baruch S, Harush A, et al. Tic disorders and the premonitory urge. J Neural Transm. 2010;117:277–284.
  • Rajagopal S, Seri S, Cavanna AE. Premonitory urges and sensorimotor processing in Tourette syndrome. Behav Neurol. 2013;27:65–73.
  • Crossley E, Cavanna AE. Sensory phenomena: clinical correlates and impact on quality of life in adult patients with Tourette syndrome. Psychiatry Res. 2013;209:705–710.
  • Crossley E, Seri S, Stern JS, et al. Premonitory urges for tics in adult patients with Tourette syndrome. Brain Dev. 2014;36:45–50.
  • Eddy CM, Cavanna AE. Premonitory urges in adults with complicated and uncomplicated Tourette syndrome. Behav Modif. 2014;38:264–275.
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. ( DSM-5). Arlington (VA): American Psychiatric Publishing; 2013.
  • Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 2009;67:475–483.
  • Scharf JM, Miller LL, Gauvin CA, et al. Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord. 2015;30:221–228.
  • Freeman RD, Fast DK, Burd L, et al. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol. 2000;42:436–447.

• Largest study to date on the clinical phenotype of Tourette syndrome, encompassing tics and behavioral comorbidities.

  • Hassan N, Cavanna AE. The prognosis of Tourette syndrome: implications for clinical practice. Funct Neurol. 2012;27:23–27.
  • Robertson MM. Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med. 2011;72:100–107.
  • Cavanna AE, Rickards HE. The psychopathological spectrum of Gilles de la Tourette syndrome. Neurosci Biobehav Rev. 2013;37:1008–1015.
  • Lombroso PJ, Scahill L. Tourette syndrome and obsessive-compulsive disorder. Brain Dev. 2008;30:231–237.
  • Eddy CM, Cavanna AE. Tourette syndrome and obsessive compulsive disorder: compulsivity along the continuum. J Obsessive Compuls Relat Disord. 2014;3:363–371.
  • El Malhany N, Gulisano M, Rizzo R, et al. Tourette syndrome and comorbid ADHD: causes and consequences. Eur J Pediatr. 2014;174:279–288.
  • Simpson HA, Jung L, Murphy TK. Update on attention-deficit/hyperactivity disorder and tic disorders: a review of the current literature. Curr Psychiatry Rep. 2011;13:351–356.
  • Robertson MM. Mood disorders and Gilles de la Tourette’s syndrome: an update on prevalence, etiology, comorbidity, clinical associations, and implications. J Psychosom Res. 2006;61:349–358.
  • Frank M, Piedad J, Rickards H, et al. The role of impulse control disorders in Tourette syndrome: an exploratory study. J Neurol Sci. 2011;310:276–278.
  • Wright A, Rickards H, Cavanna AE. Impulse control disorders in Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci. 2012;24:16–27.
  • Cox JH, Cavanna AE. Irritability symptoms in Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci. 2015;27:42–47.
  • Felling RJ, Singer HS. Neurobiology of Tourette syndrome: current status and need for further investigation. J Neurosci. 2011;31:12387–12395.
  • Singer HS. Tourette syndrome and other tic disorders. Handb Clin Neurol. 2011;100:641–657.
  • Bronfeld M, Bar-Gad I. Tic disorders: what happens to the basal ganglia? Neuroscientist. 2013;19:101–108.
  • Worbe Y, Marrakch-Kacem L, Lecomte S, et al. Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome. Brain. 2015;138(2):472–482.
  • Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol. 2012;8:203–213.
  • Ali F, Morrison KE, Cavanna AE. The complex genetics of Gilles de la Tourette syndrome: implications for clinical practice. Neuropsychiatry. 2013;3:321–330.
  • Dietrich A, Fernandez TV, King RA, et al. The Tourette International Collaborative Genetics (TIC Genetics) study, finding the genes causing Tourette syndrome: objectives and methods. Eur Child Adolesc Psychiatry. 2015;24:141–151.
  • Davis LK, Yu D, Keenan CL, et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013;9:e1003864.
  • Scharf JM, Yu D, Mathews CA, et al. Genome-wide association study of Tourette’s syndrome. Mol Psychiatry. 2013;18:721–728.
  • Madhusudan N, Cavanna AE. The role of immune dysfunction in the development of tics and susceptibility to infections in Tourette syndrome: a systematic review. Basal Ganglia. 2013;3:77–84.
  • Martino D, Zis P, Buttiglione M. The role of immune mechanisms in Tourette syndrome. Brain Res. 2015;1617:126–143.
  • Roessner V, Plessen KJ, Rotherberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173–196.
  • Waldon K, Hill S, Termine C, et al. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol. 2013;26:265–273.
  • Frank M, Cavanna AE. Behavioural treatments for Tourette syndrome: an evidence-based review. Behav Neurol. 2013;27:105–117.
  • McGuire JF, Piacentini J, Brennan EA, et al. A meta-analysis of behavior therapy for Tourette Syndrome. J Psychiatr Res. 2014;50:106–112.
  • Porta M, Sassi M, Ali F, et al. Neurosurgical treatment for Gilles da la Tourette syndrome: the Italian perspective. J Psychosom Res. 2009;67:585–590.
  • Cavanna AE, Eddy CM, Mitchell R, et al. An approach to deep brain stimulation for severe treatment-refractory Tourette syndrome: the UK perspective. Br J Neurosurg. 2011;25:38–44.
  • Schrock LE, Mink JW, Woods DW, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015;30:448–471.
  • Thomas R, Cavanna AE. The pharmacology of Tourette syndrome. J Neural Transm. 2013;120:689–694.
  • Cavanna AE, Selvini C, Termine C, et al. Tolerability profile of clonidine in the treatment of adults with Tourette syndrome. Clin Neuropharmacol. 2012;35:269–272.
  • Gulisano M, Calì PV, Cavanna AE, et al. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32:1213–1217.
  • Himle MB, Woods DW, Piacentini JC, et al. Brief review of habit reversal training for Tourette syndrome. J Child Neurol. 2006;21:719–725.
  • Dutta N, Cavanna AE. Effectiveness of habit reversal therapy in the treatment of Tourette syndrome and other chronic tic disorders: a systematic review. Funct Neurol. 2013;28:7–12.
  • Steeves TD, Fox SH. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Prog Brain Res. 2008;172:495–513.
  • Wong DF, Brasić JR, Singer HS, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33:1239–1251.
  • Udvardi PT, Nespoli E, Rizzo F, et al. Nondopaminergic neurotransmission in the pathophysiology of Tourette syndrome. Int Rev Neurobiol. 2013;112:95–130.
  • Haas HL, Sergeevva OA, Sebach O. Histamine in the nervous system. Physiol Rev. 2008;88:1183–1241.
  • Panula P, Airaksinen MS, Pirvola U, et al. A histamine-containing neuronal system in human brain. Neuroscience. 1990;34:127–132.
  • Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol. 2001;63:637–672.
  • Kohler CA, Da Silva WC, Benetti F, et al. Histaminergic mechanisms for modulation of memory systems. Neural Plast. 2011;2011:328602.
  • Flik G, Dremencov E, Cremers TI. The role of cortical and hypothalamic histamine-3 receptors in the modulation of central histamine neurotransmission: an in vivo electrophysiology and microdialysis study. Eur J Neurosci. 2011;34:1747–1755.
  • Ferrada C, Ferre S, Casado V, et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology. 2008;55:190–197.
  • Ellenbroek BA. Histamine H3 receptors, the complex interaction with dopamine and its implications for addiction. Br J Pharmacol. 2013;170:46–57.
  • Hallett M. Tourette syndrome: update. Brain Dev. 2015;37:651–655.
  • Nuutinen S, Panula P, Thurmond RL. Histamine in neurotransmission and brain diseases. Adv Exp Med Biol. 2010;709:95–107.
  • Baronio D, Gonchoroski T, Castro K, et al. Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. Ann Gen Psychiatry. 2014;13:34.
  • Bañuelos-Cabrera I, Valle-Dorado MG, Aldana BI, et al. Role of histaminergic system in blood-brain barrier dysfunction associated with neurological disorders. Arch Med Res. 2014;45:677–686.
  • Shan L, Bao AM, Swaab DF. The human histaminergic system in neuropsychiatric disorders. Trends Neurosci. 2015;38:176–177.
  • Shan L, Dauvilliers Y, Siegel JM. Interactions of the histamine and hypocretin systems in CNS disorders. Nat Rev Neurol. 2015;11:401–413.
  • Panula P, Rinne J, Kuokkanen K, et al. Neuronal histamine deficit in Alzheimer’s disease. Neuroscience. 1998;82:993–997.
  • Naddafi F, Mirshafiey A. The neglected role of histamine in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2014;28:327–336.
  • Stasiak A, Mussur M, Unzeta M, et al. The central histamine level in rat model of vascular dementia. J Physiol Pharmacol. 20011;62:549–558.
  • Rinne JO, Anichtchik OV, Eriksson KS, et al. Increased brain histamine levels in Parkinson’s disease but not in multiple system atrophy. J Neurochem. 2002;81:954–960.
  • Yokoyama H, Iinuma K. Histamine and seizures: implications for the treatment of epilepsy. CNS Drugs. 1996;5:321–330.
  • Scherkl R, Hashem A, Frey HH. Importance of histamine for seizure susceptibility. Agents Actions Suppl. 1991;33:85–89.
  • Moher D, Liberati A, Tetzlaff J, et al., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–1012.
  • Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. L-histidine decarboxylase and Tourette’s syndrome. N Engl J Med. 2010;362:1901–1908.

•• Analysis of linkage in a two-generation pedigree which led to the identification of a rare functional mutation in the HDC gene encoding l-histidine decarboxylase, pointing to a role for histaminergic neurotransmission in the mechanism and modulation of Tourette syndrome.

  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. text revision (DSM-IV-TR). Arlington (VA): American Psychiatric Publishing; 2000.
  • Lei J, Deng X, Zhang J, et al. Mutation screening of the HDC gene in Chinese Han patients with Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet. 2012;159:72–76.
  • Fernandez TV, Sanders SJ, Yurkiewicz IR, et al. Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biol Psychiatry. 2012;71:392–402.
  • Karagiannidis I, Dehning S, Sandor P, et al. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet. 2013;50:760–764.
  • Castellan Baldan L, Williams KA, Gallezot JD, et al. Histidine decarboxylase deficiency causes Tourette syndrome: parallel findings in humans and mice. Neuron. 2014;81:77–90.

•• Histidine decarboxylase knockout mice exhibited potentiated tic-like behaviors, which were mitigated by the dopamine D2 antagonist haloperidol and by histamine infusion into the brain.

  • Rapanelli M, Frick LR, Pogorelov V, et al. Dysregulated intracellular signalling in the striatum in a pathophysiologically grounded model of Tourette syndrome. Eur Neuropsychopharmacol. 2014;24:1896–1906.
  • Schneider EH, Neumann D, Seifert R. Modulation of behaviour by the histaminergic system: lessons from HDC-, H3R- and H4R-deficient mice. Neurosci Biobehav Rev. 2014;47:101–121.
  • Dere E, De Souza-Silva MA, Topic B, et al. Histidine-decarboxylase knockout mice show deficient nonreinforced episodic object memory, improved negatively reinforced water-maze performance, and increased neo- and ventro-striatal dopamine turnover. Learn Mem. 2003;10:510–519.
  • Xu M, Li I, Ohtsu H, et al. Histidine decarboxylase knockout mice, a genetic model of Tourette syndrome, show repetitive grooming after induced fear. Neurosci Lett. 2015;595:50–53.
  • Shafii M. The effects of sympathomimetic and antihistaminic agents on chronic motor tics and Tourette’s disorder. N Engl J Med. 1986;315:1228–1229.
  • Hartmann A, Worbe Y, Arnulf I. Increasing histamine neurotransmission in Gilles de la Tourette syndrome. J Neurol. 2012;259:375–376

• Single case report showing that treatment by an inverse agonist of the H3 receptor (raising histaminergic neurotransmission) resulted in improvement in a Tourette syndrome patient’s narcolepsy without changes in his tics, thus warranting controlled clinical trials of H3 receptor reverse agonists in Tourette syndrome.

  • Erenberg G. The relationship between Tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol. 2005;12:217–221.
  • Robertson MM. Attention deficit hyperactivity disorder, tics and Tourette’s syndrome: the relationship and treatment implications. Eur Child Adolesc Psychiatry. 2006;15:1–11.
  • Jucaite A, Takano A, Boström E, et al. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. Int J Neuropsychopharmacol. 2013;16:1231–1239.
  • Bolam JP, Ellender TJ. Histamine and the striatum. Neuropharmacology. 2015. pii: S0028-3908(15)30059-9. doi:10.1016/j.neuropharm.2015.08.013. [Epub ahead of print].
  • Alsobrook JP, Pauls DL. A factor analysis of tic symptoms in Gilles de la Tourette syndrome. Am J Psychiatry. 2002;159:291–296.
  • Eapen V, Fox-Hiley P, Banerjee S, et al. Clinical features and associated psychopathology in a Tourette Syndrome cohort. Acta Neurol Scand. 2004;109:255–260.
  • Storch EA, Murphy TK, Geffken GR, et al. Further psychometric properties of the Tourette’s Disorder Scale-Parent Rated version (TODS-PR). Child Psychiatry Hum Dev. 2004;35:107–120.
  • Robertson MM, Cavanna AE. The Gilles de la Tourette syndrome: a principal component factor analytic study of a large pedigree. Psychiatric Genet. 2007;17:143–152.
  • Robertson MM, Althoff RR, Hafez A, et al. A principal components analysis of a large cohort of patients with Gilles de la Tourette syndrome. Br J Psychiatry. 2008;193:31–36.
  • Cavanna AE, Critchley HD, Orth M, et al. Dissecting the Gilles de la Tourette spectrum: a factor analytic study on 639 patients. J Neurol Neurosurg Psychiatry. 2011;82:1320–1323.
  • Mathews CA, Jang KL, Herrera LD, et al. Tic symptom profiles in subjects with Tourette syndrome from two genetically isolated populations. Biol Psychiatry. 2007;61:292–300.
  • Grados MA, Mathews CA, the Tourette Syndrome Association International Consortium for Genetics. Latent class analysis of Gilles de la Tourette syndrome using comorbidities: clinical and genetic implications. Biol Psychiatry. 2008;64:219–225.
  • Rodgers S, Müller M, Kawohl W, et al. Sex-related and non-sex-related comorbidity subtypes of tic disorders: a latent class approach. Eur J Neurol. 2014;21:700–707.
  • Rapanelli M, Pittenger C. Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions. Neuropharmacology. 2015. pii: S0028-3908(15)30065-4. doi:10.1016/j.neuropharm.2015.08.019. [Epub ahead of print].
  • Termine C, Selvini C, Rossi G, et al. Emerging treatment strategies in Tourette syndrome: what’s in the pipeline? Int Rev Neurobiol. 2013;112:445–480.
  • Cavanna AE, David K, Bandera V, et al. Health-related quality of life in Gilles de la Tourette syndrome: a decade of research. Behav Neurol. 2013;27:83–93.
  • Cavanna AE, Luoni C, Selvini C, et al. Disease-specific quality of life in young patients with Tourette syndrome. Pediatr Neurol. 2013;48:111–114.
  • Conelea CA, Busch AM, Catanzaro MA, et al. Tic-related activity restriction as a predictor of emotional functioning and quality of life. Compr Psychiatry. 2014;55:123–129.
  • Yuce M, Guner SN, Karabekiroglu K, et al. Association of Tourette syndrome and obsessive-compulsive disorder with allergic diseases in children and adolescents: a preliminary study. Eur Rev Med Pharmacol Sci. 2014;18:303–310.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.